ADVANCING TO GLOBAL LAUNCHES & CONTINUED PIPELINE PROGRESS

November 2024

Nasdaq/AIM:HCM | HKEX:13

HUTCHMED

Safe harbor statement & disclaimer

The performance and results of operations of the HUTCHMED Group contained within this presentation are historical in nature, and past performance is no guarantee of future results.

This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words like "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "pipeline," "could," "potential," "first-in-class," "best-in-class," "designed to," "objective," "guidance," "pursue," or similar terms, or by express or implied discussions regarding potential drug candidates, potential indications for drug candidates or by discussions of strategy, plans, expectations or intentions. You should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that any of our drug candidates will be approved for sale in any market, that any approvals which are obtained will continue to remain valid and effective , or that the sales of products marketed or otherwise commercialized by HUTCHMED and/or its collaboration partners (collectively, "HUTCHMED Products") will achieve any particular revenue or net income levels. In particular, management's expectations could be affected by, among other things: unexpected regulatory actions or delays or government regulation generally, including, among others; the uncertainties inherent in research and development, including the inability to meet our key study assumptions regarding enrollment rates, timing and availability of subjects meeting a study's inclusion and exclusion criteria and funding requirements, changes to clinical protocols, unexpected adverse events or safety, quality or manufacturing issues; and the inability of a drug candidate to meet the primary or secondary endpoint of a study; the inability of a drug candidate to obtain regulatory approval in different jurisdictions or the utilization, market acceptance and commercial success of HUTCHMED Products after obtaining regulatory approval; the emergence of competing drugs and product candidates that may be superior to, or more cost effective than, HUTCHMED'S Products and drug candidates; the impact of studies (whether conducted by HUTCHMED or others and whether mandated or voluntary) or recommendations and guidelines from governmental authorities and other third parties on the commercial success of HUTCHMED Products and candidates in development; the costs of developing, producing and selling HUTCHMED Products; the ability of HUTCHMED to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; global trends toward health care cost containment, including ongoing pricing pressures; uncertainties regarding actual or potential legal proceedings, including, among others, actual or potential product liability litigation, litigation and investigations regarding sales and marketing practices, intellectual property disputes, and government investigations generally; general economic and industry conditions, including uncertainties regarding the effects of the persistently weak economic and financial environment in many countries and uncertainties regarding future global exchange rates , the risk that HUTCHMED's ADSs could be barred from trading in the United States as a result of the Holding Foreign Companies Accountable Act and the rules promulgated thereunder, and the impact of pandemics or other health crises in China or globally. For further discussion of these and other risks, see HUTCHMED's filings with the U.S. Securities and Exchange Commission, on AIM and with The Stock Exchange of Hong Kong Limited. HUTCHMED is providing the information in this presentation as of this date and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.

This presentation is intended for investors only. Information concerning pharmaceuticals (including compounds under development) contained within this material is not intended as advertising or medical advice.

Some of the clinical data in this presentation relating to HUTCHMED's products or its investigational drug candidates is from pre-clinical studies or early phase, single-arm clinical trials. When such data or data from later stage trials are presented in relation to other investigational or marketed drug products, the presentation and discussion are not based on head-to-head trials between HUTCHMED's investigational drug candidates and other products unless specified in the trial protocol. HUTCHMED is still conducting pre-clinical studies and clinical trials and, as additional patients are enrolled and evaluated, data on HUTCHMED's investigational drug candidates may change.

In addition, this presentation contains statistical data, third-party clinical data and estimates that HUTCHMED obtained from industry publications and reports generated by third-party market research firms, including Frost & Sullivan, IQVIA, independent market research firms, clinical data of competitors, and other publicly available data. All patient population, market size and market share estimates are based on Frost & Sullivan or QuintilesIMS/IQVIA research, unless otherwise noted. Although HUTCHMED believes that the publications, reports, surveys and third-party clinical data are reliable, HUTCHMED has not independently verified the data and cannot guarantee the accuracy or completeness of such data. You are cautioned not to give undue weight to this data. Such data involves risks and uncertainties and are subject to change based on various factors, including those discussed above.

Nothing in this presentation or in any accompanying management discussion of this presentation constitutes, nor is it intended to constitute or form any part of: (i) an invitation or inducement to engage in any investment activity, whether in the United States, the United Kingdom, Hong Kong or in any other jurisdiction; (ii) any recommendation or advice in respect of any securities of HUTCHMED; or (iii) any offer or an invitation to induce an offer by any person for the sale, purchase or subscription of any securities of HUTCHMED. Information concerning pharmaceuticals (including compounds under development) contained within this material is not intended as advertising or medical advice.

No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information, or opinions contained herein. Neither HUTCHMED, nor any of HUTCHMED's advisors or representatives shall have any responsibility or liability whatsoever (for negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection with this presentation. The information set out herein may be subject to updating, completion, revision, verification and amendment and such information may change materially.

All references to "HUTCHMED" as used throughout this presentation refer to HUTCHMED (China) Limited and its consolidated subsidiaries and joint ventures unless otherwise stated or indicated by context. This presentation should be read in conjunction with HUTCHMED's results for the period ended June 30, 2024 and HUTCHMED's other SEC filings and announcements published in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited copies of which are available on HUTCHMED's website (www.hutch-med.com).

Use of Non-GAAP Financial Measures - This presentation may include certain non-GAAP financial measures. Please see the section of the HUTCHMED results announcement titled "Use of Non-GAAP Financial Measures and Reconciliation" for further information relevant to the interpretation of these financial measures and reconciliations of these financial measures to the most comparable GAAP measures.

HUTCHMED today: a global science-focused biopharma

Fully integrated R&D and commercialization platform

Global novel **drug discovery & manufacturing** operations

20+ years novel drug discovery –more than **20 novel drug candidates**[1] discovered in-house

New flagship factory to expand capacity by 5x

Listed on the LSE (HCM), NASDAQ (HCM), and HKEX (13)

Clinical development & regulatory operations **in all major markets**

- **China, US, EU & Japan** clinical capabilities
- First **3 novel oncology medicines approved in China**
- **1 US, EU and JP launched**

Commercial teams in China

- **Oncology commercial team covering >3,000 hospitals in China**
- Above 800 sales in China
- Commercial partnering outside of China



[1] Excludes in-licensed compound tazemetostat. Includes two clinical stage NMEs being developed by Inmagene.

H1 2024: strong execution on strategic direction

STRATEGIC DELIVERY

✓ **Continued revenue momentum with substantial cash balance to support growth**

- Reiterate full year 2024 guidance for Oncology/Immunology consolidated revenue of $300 to $400 million
- On track to become self-sustaining

✓ **Globalization of fruquintinib continues, broader pipeline makes strong progress**

PRODUCTS & PIPELINE PROGRESS

LATE STAGE

- ✓ Fruq China NDA accepted (EMC)
- ✓ Savo China sNDA accepted (add 1L MET EXON14 NSCLC)
- ✓ Savo SAVANNAH completed enrollment (2L NSCLC)

2nd and 3rd WAVE

- ✓ Sovle China NDA filed with priority review (ITP) & wAIHA Phase III initiated
- ✓ Taz China NDA filed with priority review (FL)
- ✓ Initiated IDH1/2 inhibitor HMPL-306 Phase III RAPHAEL study

GLOBAL COMMERCIAL DELIVERY

✓ **Speedy FRUZAQLA® US launch** with strong early patient uptake; H1 in-market sales reached $130.5m

✓ **FRUZAQLA® EU and Japan approved**

✓ **Strong commercial execution,** combined product revenue in-market sales grew +140% (+145% CER)

CER = at constant exchange rate
In-market sales = For ELUNATE®, FRUZAQLA® and ORPATHYS®, mainly represents total sales to third parties as provided by Lilly, Takeda and AstraZeneca, respectively

HUTCHMED registration/potential registration studies

15+ programs for seven drug candidates supporting potential near-term NDA filings

Drug	Study	Target Disease	Region	Design (N, arms, 1° endpoint)	Status	Est. (s)NDA filing if positive
FRUQ**	**FRESCO-2**	3L+ colorectal cancer	Global	~690, treatment vs. BSC, OS	US, EU and JP approved	US, EU and JP approved
SOVLE	**ESLIM-01**	2L immune thrombocytopenia	China	~180, 2 arms (placebo), DRR	NDA in China accepted January 2024 priority review status	Review ongoing
SAVO*	**Confirm**	NSCLC, MET Exon 14 alteration	China	~160, 1 arm, ORR	sNDA in China accepted March 2024	Review ongoing
FRUQ^^	**FRUSICA-1**	2L EMC, combo with PD-1	China	~140, 1 arm, ORR	NDA in China accepted April 2024 China BTD, priority review status	Review ongoing
TAZ^	**Bridging**	3L follicular lymphoma	China	~40, 2 arms (EZH2+ or wt), ORR	NDA in China accepted July 2024 priority review status	Review ongoing
SAVO*	**SAVANNAH**	2/3L TAGRISSO® refractory NSCLC, MET+	Global	New cohort for potential AA, 1 arm, ORR	LPI Feb '24	Late 2024
FRUQ^^	**FRUSICA-2**	2L RCC, combo with PD-1	China	~260, 2 arms, PFS	LPI Dec'23	2025
SURU	**SURTORI-01**	2L NEC, combo with PD-1	China	~190, combo vs. chemo, OS	Enrolling	2025
SAVO*	**SACHI**	2L EGFR TKI refractory NSCLC, MET+	China	~250, combo vs. chemo, PFS	Enrolling	2025
SAVO*	**GASTRIC**	3L GC, MET amplified	China	~60, 1 arm, ORR	Enrolling Reg. cohort opened Mar 2023	2025
SOVLE	**ESLIM-02**	2L wAIHA	China	~110, 2 arms (placebo), Hb response	FPI Mar'24	2026
SAVO*	**SANOVO**	1L EGFRm+ NSCLC, MET+	China	~320, combo vs. Tagrisso, PFS	Enrolling	2026
SAVO*	**SAMETA**	MET driven PRCC, combo with PD-L1	Global	~200, 3 arms combo vs. monos, PFS	Enrolling	2026
SAVO*	**SAFFRON**	2/3L TAGRISSO® refractory NSCLC, MET+	Global	~320, combo vs. chemo, PFS	Enrolling	2026
HMPL-453	**IHCC, FGFR2**	IHCC, FGFR2 fusion	China	~90, 1 arm, ORR	Enrolling Reg. cohort opened Mar 2023	2026
HMPL-306	**RAPHAEL**	IDH1/2+ r/r AML	China	~320, 2 arms, OS	FPI May'24	2027

* In collaboration with AstraZeneca ^ In collaboration with Ipsen ** In collaboration with Takeda ^^ In collaboration with Lilly

Commercial delivery

Novel oncology products continue to bring growth

FRUZAQLA® (fruquintinib) : rapid patient uptake after US launch

Colon cancer is the **3rd most common cancer** and **2nd leading cause of cancer-related deaths** worldwide[1]

In-market sales[2] *(US$ millions)*



Fruzaqla®
(fruquintinib) capsules
5 mg • 1 mg

- **Partnered with Takeda outside China, US$20 million sales milestone payment triggered**
- **Exceeding expectation with significant uptake in the US**
  - One of the most prescribed therapies in 4L+ (29% share[4])
  - Continue to see strong uptake in 3L (10% share[4])
- Inclusion in NCCN and ESMO guidelines
- Approval in Japan with Takeda's strength in CRC through VECTIBIX®
- JP/EU reimbursement decisions anticipated

9 regulatory approvals received in <1 year

NCCN = National Comprehensive Cancer Network; ESMO = European Society for Medical Oncology
[1] International Agency for Research on Cancer
[2] Takeda reported FRUZAQLA® revenue of JPY23.1 billion for FY2024 Q2 (Apr-Sep 2024); USD1=JPY154
[3] **FRUZAQLA® FY2024 (Apr 2024 - Mar 2025) forecast upgraded to YOY >300% from YOY >100% based on Takeda's FY2024 Q2 results**
[4] According to Market share data based on IQVIA (July 2024), as reported in Takeda's FY2024 Q2 results

ELUNATE® (fruquintinib) remains market leader in 3L CRC

HUTCHMED

ELUNATE®
Fruquintinib Capsules

In-market sales *(US$ millions)*



Continued to be the leader in 3L CRC market in H1 2024

- HK 3L CRC approval in 2024
- China NRDL 2nd round successfully renewed at current terms
- ~105,000 est. 3L CRC new patients in 2024

Strong competitive position

- Inclusion in CSCO, CACA CRC Guidelines, Pan-Asian mCRC Clinical Practice and NCCN Guidelines
- **Maintaining leadership in patient share in 3L CRC** (IQVIA[1]) in China

	Q4-19	Q4-20	Q4-21	Q4-22	Q2-23	Q2-24
ELUNATE®	25%	33%	39%	44%	47%	**47%**
STIVARGA®	32%	35%	34%	29%	26%	26%
FTD+TPI[2]	0%	0%	5%	12%	13%	17%

CSCO = New treatment guidelines with Chinese Society of Clinical Oncology, CACA = Chinese Anti-Cancer Association; NCCN = National Comprehensive Cancer Network
[1] IQVIA audit data in proprietary post-launch research panel of mainly Class 3 hospitals in Top 30 cities in China
[2] including Lonsurf® and its generics

SULANDA® (surufatinib) increasing patient access & duration of treatment

In-market sales *(US$ millions)*



Prescriptions increased in H1 2024

- NRDL successfully renewed at current terms
- ~40,000 est. new NET/NEN patients in 2024
- Increasing patient access after inclusion on the NRDL and long duration of treatment

Maintaining market share position

- Included in CSCO & CACA NENs Guidelines, China GEP NETs Expert Consensus and CMA NENs Consensus
- Ranked the 2nd brand in NET market since Q3 2022, **surpassed Sutent® & Afinitor®** (IQVIA[1])

	Q3-21	Q1-22	Q3-22	Q1-23	Q4-23
SULANDA®	7%	14%	16%	17%	21%
Somatostatin analogues	53%	47%	42%	36%	38%
Sutent®	14%	14%	14%	13%	10%
Afinitor®	10%	9%	10%	11%	9%

CSCO = New treatment guidelines with Chinese Society of Clinical Oncology, CACA = Chinese Anti-Cancer Association; CMA = China Medical Association
[1] IQVIA NET Tracking Study conducted April 2023.

ORPATHYS® (savolitinib) first-in-class MET inhibitor

In-market sales *(US$ millions)*



NRDL inclusion from March 1, 2023

- In-market sales +22% at CER in H1 2024
- Account for 71% of TKI market share despite strong market competition and the inclusion of 2 drugs on the NRDL

Potential expansion into 1L MET Exon 14 NSCLC in 2025

Publications

- ELCC March 2024 (PFS: 13.7mo; ORR: 62.1%); WCLC 2023

Inclusion in key treatment guidelines

- NHC, CSCO, CACA, CMA, CTONG
- MET testing now recommended as SOC for late-stage NSCLC

Potential NSCLC indications in combination with TAGRISSO®

- Biomarker specific approach
- Partnered with AZ worldwide

ELCC = European Lung Cancer Congress; WCLC = World Conference on Lung Cancer;
NHC = National Health Commission; CSCO = Chinese Society of Clinical Oncology; CACA = Chinese Anti-Cancer Association; CMA = China Medical Association; CTONG = Chinese Thoracic Oncology Group

Sovleplenib launch preparation

Addressing unmet medical needs with strategic priorities and comprehensive launch planning

Source of Business Priority

1. **Capture** previously treated TPO/TPO-RA patients, ensuring continuity of care and improved efficacy
2. **Address** the needs of patients with an increased thrombotic risk, such as those with coronary artery diseases, diabetes, advanced age, or obesity
3. **Target** the 2nd line treatment market after glucocorticoids, especially for patients who:
   - seek long-term stable platelets
   - focus on quality of life and don't want to comprise their lifestyle
4. **Employ** a combination therapy strategy together with glucocorticoids

- Understand China ITP **unmet medical needs**
- Highlight **Syk unique MOA and differentiation**

- Regulatory approval, production and distribution, price, brand plan etc.

- **Equip field force** (sales, MSL, and regional marketing)
- **Mobilize all internal resource** to support the new launch including distribution, market access, R&D, etc.

MSL = Medical Science Liaison

Pipeline updates

15+ potential NDAs & sNDAs in the next 3 years

Savolitinib: major late-stage expansion

7 registrational studies 3 global & 4 in China

Global **2/3L TAGRISSO® refractory NSCLC w/ MET aberration**

WCLC 2022

SAVANNAH study:

16 Oct 2024, registrational study demonstrated a high, clinically meaningful and durable ORR

NDA filing by end of 2024

Enrollment completion in Feb 2024

China **MET Exon14 skipping NSCLC**

ELCC 2024

Confirmatory Phase IIIb study:

China sNDA accepted March 2024

NDA conditional approval in Jun 2021

China **2L EGFR TKI refractory NSCLC w/ MET amplification**

SACHI study:

Enrollment completion by end of 2024

Savolitinib + TAGRISSO® Phase III registration study

Ongoing enrollment

Global **2/3L TAGRISSO® refractory NSCLC w/ MET aberration**

SAFFRON study:

Savolitinib + TAGRISSO® Phase III registration study

Global **MET-driven Papillary Renal Cell Carcinoma (PRCC)**

SAMETA study:

Savolitinib + IMFINZI® vs. SUTENT® monotherapy vs. IMFINZI® monotherapy Phase III registration study

China **1L EGFRm+ NSCLC w/ MET overexpression**

SANOVO study:

Savolitinib + TAGRISSO® Phase III registration study

China **Gastric cancer w/ MET amplification**

AACR 2023

Single arm study with potential for registration

Registration cohort FPI Mar 2023

China Breakthrough designation

2L EGFRm+ NSCLC w/ MET aberration market potential

HUTCHMED

China market

US$850m -$1.2bn

Global Market

US$750m – US$1.1bn

NSCLC

~85% of all lung cancer[1]

EGFR mutations

- **~20%** in US[2]
- **~50%** in Asia[3]

MET positive - high

34% of EGFRm NSCLC patients[4]

[1] American Cancer Society. What is Lung Cancer? Accessed on 28 Aug 2024
[2] Estelamari R, et al. Prevalence of EGFR mutation testing in early-stage lung cancer: Implications of the ADAURA trial for clinical practice. Journal of Clinical Oncology May 28 2021, volume 39, number 15_suppl
[3] Barbara M, et al. Worldwide Prevalence of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Meta-Analysis. Molecular Diagnosis & Therapy 2022, volume 27, page 7-18
[4] WCLC 2022 Abstract # EP08.02-140. DOI: 10.1016/j.jtho.2022.07.823;

Savolitinib: 2L EGFRm+ NSCLC w/ MET aberration

- An oral-only, chemo-free option for MET+ patients whose EGFRm+ NSCLC progressed on TAGRISSO®
- 16 Oct 2024, SAVANNAH registrational study demonstrated ***a high, clinically meaningful and durable ORR***

SAVANNAH MET specific (100% 3rd gen; Phase II)[1]

N=185* 300mg QD	MET positive -high IHC90+ and/or FISH10+		MET positive -low IHC50–90 and/or FISH 5-10	
Prevalence among patients screened	34%		28%	
Prior Chemo	20%	No prior chemo subset	18%	No prior chemo subset
Administration	Oral			
No of pts	n=108	n=87	n=77	n=63
ORR	49%	52%	9%	10%
mPFS	7.1m	7.2m	2.8m	2.8m
mDoR	9.3m	9.6m	6.9m	7.3m

All comers, not MET specific efficacy data of EGFRm pts

	MARIPOSA-2[2] (Phase III)	TL01[3] (Phase III)	ORIENT-31[4] [5] (Phase III)	HARMONi-A[7] (Phase III)	TROP2-ADC[6] (Phase I/II)	BL-B01D1[8] (Phase I)
Patient Screening	Post Osimertinib *100% 3rd gen*	AGA pts	nsqNSCLC after EGFR-TKI *37% 3rd gen*	Post EGFR-TKI *86% 3rd gen*	Previously treated *45% 3rd gen*	Post EGFR-TKI *89% 3rd gen*
All IV drugs	Amivantamab (EGFR/MET) +chemo	Dato-DXd (TROP2-ADC)	Sintilimab (PD-1) +bev +chemo	Ivonescimab (PD-1/VEGF) +chemo	SKB264 (TROP2-ADC)	B01D1 (EGFR/HER3 ADC)
No of EGFRm pts	n=131	n=50 (AGAs including EGFR, ALK, NTRK, etc)	n=158	n=322	n=22	n=38
ORR	53%	26.4% (n=604, mostly non-AGA)	48%	51%	60%	63%
mPFS	6.3m	6.8m	7.2m	7.06m	11.5m	6.9m
mDoR	6.9m	7.1m	8.5m	n/a	8.7m	n/a

*Evaluable for efficacy defined as dosed patients with measurable disease at baseline who had ≥2 on-treatment RECIST scans. Excludes eight patients with invalid or missing test results for IHC90+ and/or FISH10+ status, these patients were excluded from the subgroup analyses based on MET levels.

[1] WCLC 2022 Abstract # EP08.02-140. DOI: 10.1016/j.jtho.2022.07.823; [2] ESMO 2023 Abstract #LBA15, DOI: 10.1016/j.annonc.2023.10.117 ; [3] ESMO 2023 Abstract #509MO; [4] The Lancet Respiratory Medicine 2023 , DOI: 10.1016/S2213-2600(23)00135-2;
[5] ESMO 2022 Abstract #LBA58, DOI: 10.1016/j.annonc.2022.08.060; [6] Wenfeng F, et al. Updated efficacy and safety of anti-TROP2 ADC SKB264 (MK-2870) for previously treated advanced NSCLC in Phase 2 study; AACR 2024; [7] ASCO 2024 Abstract #8508, DOI 10.1200/JCO.2024.42.16_suppl.8508;
[8] Li Zhang, L-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate, in patients with non-small cell lung cancer: Updated results from first-in-human phase I study; ESMO 2023

Fruquintinib 3L CRC: US FDA approved Nov 2023

Competitive profile demonstrated in multi-regional clinical trial



Fruquintinib is well tolerated with a safety profile consistent with the previously established monotherapy profile

	FRESCO-2 [1] [4]		CORRECT [2] [4]		RECOURSE [3] [4]	
Tolerability	**Fruquintinib**	**Placebo**	**Regorafenib**	**Placebo**	**TAS-102**	**Placebo**
Discontinuation due to AE	**20%**	**21%**	**17%**	**12%**	**4%**	**2%**
TEAE Grade ≥ 3	**63%**	**50%**	**54%**	**14%**	**69%**	**52%**
Major TEAE Grade ≥ 3						
Hypertension	14%	1%	7%	1%	n/a	n/a
Hand-foot syndrome	6%	0%	17%	<1%	n/a	n/a
Asthenia / fatigue	8%	4%	15%	9%	7%	9%
Other AEs of note	• No black box warning • Monitor blood pressure weekly for the first month and at least monthly thereafter as clinically indicated		• Blackbox warning on hepatoxicity • Monitor liver function prior to and monthly or more frequently during treatment		• Severe myelosuppression • Obtain complete blood counts prior to and on day 15 of each cycle	

Note: Illustrative comparison only. No head-to-head studies have been conducted. Study parameters differ.

[1] Dasari A, et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. *Lancet.* 2023;402(10395):41-53. doi:10.1016/S0140-6736(23)00772-9; [2] Grothey A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. *Lancet.* 2013;381(9863):303-312. doi:10.1016/S0140-6736(12)61900-X; [3] Mayer RJ, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. *N Engl J Med.* 2015;372(20):1909-1919. doi:10.1056/NEJMoa1414325; [4] USPI.

Fruquintinib Endometrial Cancer: Lead ICI combo in China

Breakthrough Therapy Designation in China for pMMR subtype

Medical need: Mortality from EMC projected to grow in China [2]



Chemotherapy remains as SOC in 1L and 2L EMC treatment in China with high unmet need in 2L setting

CDE consultation

FRUSICA-1 Trial NDA in China accepted in April 2024

Encouraging registration Phase II results [1]

IRC Assessment	
N	87 (efficacy evaluable pts)
ORR	35.6%
DCR	88.5%
mPFS	9.5 months (N=98, cutoff date Nov 15, 2023)

Registration package
N= ~140

Primary endpoint = ORR

[1] Xiaohua W. et al. Fruquintinib plus Sintilimab in Treated Advanced Endometrial Cancer (EMC) Patients (Pts) with pMMR Status: Results From a Multicenter, Single-Arm Phase 2 Study. *ASCO 2024.* Abstract5619
[2] International Agency for Research on Cancer

Fruquintinib with Sintilimab 2L Renal Cell Carcinoma : Phase II/III in China

HUTCHMED

Increase in mortality rate vs 2020 in China to outpace that of the US, EU4+UK, and Japan [1]



FRUSICA-2 Trial Phase II/III study

Primary endpoint: Progression free survival (IRC)

Secondary endpoints:

Tumor response (ORR, DCR, DoR) • Overall Survival • Safety

Eligible patients

- Histologically, cytologically confirmed RCC
- Progressed on, after or were intolerant to received 1L VEGFR-TKIs

enrollment completed Dec 2023

Fruquintinib + Sintilimab N ≈120	Axitinib or everolimus N ≈120	Contribution of component Fruquintinib mono N ≈15-20

[1] International Agency for Research on Cancer

Sovleplenib: immune thrombocytopenia purpura (ITP)

Large growing market with limited options

Limited treatment options

- Many patients do not respond or relapse to treatments like glucocorticoids, and TPO/TPO-RA [1]
- Fostamatinib, the only FDA approved Syk inhibitor, has a limited durable response rate of 18%

Poor quality of life

- ITP negatively effects quality of life due to fatigue, activity restrictions and anxiety [2]

China market: US$500m–$700m

Potential adult ITP addressable patients[3]



Global market: incidence 57k[4]

Prevalence 520K [5]

[1] Kim DS. Recent advances in treatments of adult immune thrombocytopenia. Blood Res 2022; 57: 112–19
[2] Mathias SD, Gao SK, Miller KL, et al. Impact of chronic immune thrombocytopenic purpura (ITP) on health-related quality of life: a conceptual model starting with the patient perspective. *Health Qual Life Outcomes* 2008; **6:** 13
[3] IQVIA analysis; [4] Clarivate,; Immune Thrombocytopenic Purpura Niche & Rare Disease Landscape & Forecast. 2018 Apr
[5] Prevalence estimated based on Rigel presentation and DelveInsight, only considering China and 7MM markets

Sovleplenib: a highly selective Syk inhibitor

Unmet medical needs to be addressed with next-gen Syk inhibitor Sovleplenib (HMPL-523)



Adapted from Newland A, et al. Immunotherapy (2018) 10(1), 9–25

Tackling Root Causes

Current treatments target Treg, megakaryocyte and B cells

- ✓ Long-term efficacy tapers off
- ✓ All patients become refractory and will run out of options

Syk is a validated target for ITP

- ✓ Syk offers a different mechanism by targeting both B cells & macrophages
- ✓ Fostamatinib approved in the US, Europe and Japan, moderate efficacy, dose limited by tox

Sovleplenib 2L ITP: NDA filing accepted for priority review

Sovleplenib is an efficacious option for patients with ITP

Sovleplenib encouraging Phase III results (ESLIM-01)[1]

ESLIM-01 successfully met the primary endpoint and all secondary endpoints, even in heavily treated primary ITP patients

- Oral, fast onset of efficacy – overall response rate of 71%, durable response rate of 48%
- Robust efficacy in heavily pre-treated patients (75% patients had received TPO/TPO-RA treatment)

Breakthrough Therapy Designation in China

	Sovleplenib – *300 mg, once daily*	
	Sovleplenib *0-24 weeks*	**Placebo** *0-24 weeks*
Durable response rate *(p<0.0001)*	48.4%	0.0%
Overall response rate *(p<0.0001)*	70.6%	16.1%
Use of rescue medication *(p=0.0451)*	22.2%	35.5%

[1] Renchi Y. et al. Efficacy and Safety of The Syk Inhibitor Sovleplenib (HMPL523) in Adult Patients with Primary Immune Thrombocytopenia in China (ESLIM-01): A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study. *EHA 2024 Congress;* Abstract S316

Sovleplenib shows high response rate in pre-treated patients

HUTCHMED

Durable response rate for sovleplenib and TPO-RAs were similar, even 75% patients were prior treated with TPO/TPO-RA

The efficacy of sovleplenib is better than fostamatinib

Efficacy comparison of Sovleplenib *vs* other development products

Durable response[1]



Overall response[2]



[1]Definition of durable response:
Romiplostim: platelets ≥ 50 x 10^9 /L for any 6 of the last 8 weeks of the 24-week, without rescue medication
Eltrombopag: platelets ≥ 50 x 10^9/L and ≤ 400 x 10^9 /L for 6 out of the last 8 weeks of the 26-week treatment period
Avatrombopag: proportion of participants with platelet count ≥ 50 × 10^9 /L and < 400 × 10^9 /L in ≥ 75% of weeks after the first platelet response
Hetrombopag: proportion of patients who responded at ≥ 75% of their platelet count assessments throughout 24-week treatment
Rilzabrutinib: platelets ≥ 50× 10^9 /L on ≥8 of the last 12 weeks, without rescue medication
Efgartigimod: platelets ≥ 50 x 10^9 /L on at least 4 of the last 6 scheduled visits between weeks 19 and 24 of treatment without intercurrent events
Fostamatinib: same with sovleplenib; platelet ≥50×10^9/L on at least 4 of 6 visits during weeks 14 and 24, without rescue therapy

[2]Definition of overall response:
Romiplostim:either a durable or a transient platelet response;
Eltrombopag: a shift from ≤ 30 x 10^9 /L to ≥ 50 x 10^9 /L at any time during the treatment period
Rilzabrutinib: achieved platelet counts ≥ 50 x 10^9/L; Efgartigimod: ≥ 1 platelets count ≥ 50 x 10^9/L within 24 weeks of treatment
Avatrombopag: non-disclosed
Hetrombopag: proportion of patients who responded at least once within 8 weeks
Fostamatinib: ≥1 platelet count ≥ 50×10^9/L within the first 12 weeks on treatment;
Sovleplenib: ≥ 1 platelet count ≥ 50×10^9/L, without rescue therapy;

No thrombotic events were observed in ESLIM-01 study

- Over target platelet count increased and thromboembolism are potential risks of TPO-RA for ITP. The incidence of thrombosis in ITP treated with avatrombopag is as high as 7%[1]
- The ITP patient population is relatively young, and once thrombosis occurs, it will have a serious impact on the patient 's quality of life

TEAE, n(%)	Sovleplenib ELISM-01 (n=126)	Fostamatinib FIT1 & FIT2 (n=102)[2]	Herombopag China pivotal study (n=339)[3]	Eltrombopag China label (n=466)	Romiplostim China NDA review (n=653)	Avatrombopag US label
Platelet count increased over ULN	1(0.8%)	Not reported	39 (11.5%)	/	Reported as normal ADR	Not reported
Thromboembolic events	0	Not reported	1 case of acute myocardial infarction 1 case of subclavian vein embolism	17 (3.8%)	39 (6.0%)	9 (7%)

[1] DOPTELET® (avatrombopag) FDA label
[2]James Bussel, et al. Am J Hematol. 2018;93:921–930.
[3]Mei et al. J Hematol Oncol (2021) 14:37.

Warm antibody autoimmune hemolytic anemia (wAIHA) ESLIM-02 Phase II demonstrated encouraging results

- Sovleplenib achieved an overall response of 66.7% and durable response of 47.6% in wAIHA patients by 24 weeks
- Patients crossed over from placebo also achieved a similar high response as in all patients

Efficacy	Definition	Week 0-8 (Double blind)		Week 8-24 (Open label)	Week 0-24 (Double blind + Open label)
		Sovleplenib (n=16)	Placebo (n=5)	Cross-over from placebo (n=5)	All sovleplenib (n=21)
Overall response, n (%)	Hb ≥100 g/L with an increase of ≥20 g/L from baseline	7 (43.8)	0	3 (60.0)	14 (66.7)
Durable response, n (%)	Hb ≥ 100 g/L with an increase of ≥20 g/L from baseline on 3 consecutive visits with at least 7 days interval	3 (18.8)	0	2 (40.0)	10 (47.6)

Lancet Haematology. 2024 Aug;11(8):e567-e579

Surufatinib for Pancreatic Ductal Adenocarcinoma (PDAC)

HUTCHMED

Significant unmet needs highlight growing demand for effective treatments

Market size

China Market： US$800m-$1bn
Incidence 100K [1]

Global Market： Incidence 510K[1]

Investigator-initiated trial results in 1L PDAC[3]

NASCA		AG
ORR: 50.0%	vs.	ORR: 26.9%
mPFS: 9.0mo		mPFS: 5.8mo
mOS: 13.3mo		mOS: 8.6mo

NASCA: surufatinib+ camrelizumab+nab-paclitaxel+S1; AG: nab-paclitaxel+ gemcitabine

[1] Pancreatic Cancer Action Network. Accessed June 28, 2024
[2] Sumit S. et al. Current and Future Therapies for Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2022 May; 14 (10): 2417
[3] 2024 ASCO GI #671

Hard to treat

Immunologically cold tumor, lacks sufficient mutations for the immune system to recognize tumor-specific antigens

Limited treatment efficacy

chemotherapy, surgery, and radiation have not significantly improved patient outcomes; surgery eligible only in 10-20% of patients [2]

Low survival rate

average five-year survival rate <13%[1]

HMPL-306 for IDH1/2-mutated Acute Myeloid Leukemia (AML)

HUTCHMED

Initiated IDH1/2 inhibitor HMPL-306 Phase III RAPHAEL study

IDH1/2 mutations

~15-25% of AML patients [3]

Nearly 25% of AML patients fail to achieve remission after treatment [4]

No dual inhibitor targeting both IDH1 and IDH2 mutants has been approved

- One IDH1 inhibitor in China
- Two IDH1 inhibitors and 1 IDH2 inhibitor in the US

[1] Lin J et al. IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. Ann Hematol. 2012;91(4):519-525. doi:10.1007/s00277-011-1352-7.
[2] AbbVie. (2024). Acute myeloid leukemia (AML). AbbVie Science. Retrieved July 1, 2024, from https://www.abbviescience.com/cancer-types/acute-myeloid-leukemia.html
[3] Guillermo Bravo et al. The role of IDH mutations in acute myeloid leukemia. Future Oncology 2018 (14) 10: 979-993
[4] Mianmian Gu et al. The prevalence, risk factors, and prognostic value of anxiety and depression in refractory or relapsed acute myeloid leukemia patients of North China. Medicine 98(50):p e18196, Dec 2019

CR+CRh rates in patients with IDH1 / IDH2 mutation

Phase I study[1]

CR+CRh rates in patients with *IDH1* mutation



CR+CRh rates in patients with *IDH2* mutation



	OS event, n (%)	Median OS (95% CI), month
150/250 mg group	8 (53.3)	13.4 (1.2-NR)
RP2D group	4 (36.4)	NR (0.9-NR)

	OS event, n (%)	Median OS (95% CI), month
150/250 mg group	13 (65.0)	13.1 (2.3-16.9)
RP2D group	4 (33.3)	NR (1.3-NR)

*Patients with *FLT3/RAS* mutation were excluded
CR = complete remission; CRh = CR with partial hematologic recovery; RP2D = recommended phase 2 dose
[1] EHA 2024 #P532

Financial review & outlook

Underpinned by strong financial & strategic fundamentals

H1 2024 Financial Overview

Substantial marketed products growth and reduction in R&D spending

Condensed Consolidated Statements of Operations

(In US$ millions)		H1 2024	H1 2023
Revenue:			
Oncology/Immunology – Marketed Products[1]	1	127.8	80.1
Oncology/Immunology – Takeda U/F, MS & R&D[2]		33.8	269.1
Oncology/Immunology – Other R&D[3]		7.1	10.0
Oncology/Immunology consolidated revenue	2	168.7	359.2
Other Ventures		137.0	173.7
Total revenue		**305.7**	**532.9**
Operating expenses:			
Cost of revenue		(180.2)	(208.3)
R&D expenses	3	(95.3)	(144.6)
Selling & admin. expenses	4	(57.8)	(68.3)
Total operating expenses		**(333.3)**	**(421.2)**
		(27.6)	**111.7**
Other income, net		22.8	25.4
(Loss)/income before income taxes & equity investee		**(4.8)**	**137.1**
Income tax expense		(2.9)	(2.7)
Equity investee, net of tax (SHPL)		33.8	35.1
Net income		**26.1**	**169.5**
Less: Net income attrib. to non-controlling interests		(0.3)	(0.9)
Net income attributable to HUTCHMED		**25.8**	**168.6**

O/I Consolidated Revenue

1. **Oncology product revenue up 59% (64% CER) to $128m**, mainly due to strong performance from FRUZAQLA® ($43m) demonstrating strong US demand and commercial traction since launch in Nov 2023
2. O/I consolidated revenue on track to meet FY2024 guidance ($300m-$400m)

Control over Operating Expenses

3. **R&D expense reduction** primarily due to strategic reorganization of Ex-China team and projects
   - Ex-China: $15m (H1 2023: $56m)
   - China: $80m (H1 2023: $89m)
4. **Selling & admin. expenses reduction** primarily due to tighter control over spending

[1] Consists of (a) FRUZAQLA® $42.8m (H1 2023: nil); (b) ELUNATE® $46.0m (H1 2023: $42.0m); (c) SULANDA® $25.4m (H1 2023: $22.6m); (d) ORPATHYS® $13.1m (H1 2023: $15.1m); and (e) TAZVERIK® $0.5m (H1 2023: $0.4m).
[2] Consists of (a) revenue recognition from Takeda upfront payment $18.1m (H1 2023: $258.7m); (b) revenue recognition from Takeda milestone payment $1.3m (H1 2023: nil); and (c) cost reimbursement and FTE income from Takeda $14.4m (H1 2023: 10.4m).
[3] Consists of other R&D services revenue primarily from AZ and Lilly.

2024 O/I Consolidated Revenue Guidance of $300-$400m, driven by 59% growth in O/I Marketed Product Revenue



(in US$ millions)	H1 2024	H1 2023	%Δ (CER)	H1 2024	H1 2023	%Δ (CER)
	In-market Sales[1]			**Consolidated Revenue[2]**		
FRUZAQLA® (fruquintinib)	$130.5	-	-	$42.8	-	-
ELUNATE® (fruquintinib)	$61.0	$56.3	+8% *(+13%)*	$46.0	$42.0	+9% *(+14%)*
SULANDA® (surufatinib)	$25.4	$22.6	+12% *(+17%)*	$25.4	$22.6	+12% *(+17%)*
ORPATHYS® (savolitinib)	$25.9	$22.0	+18% *(+22%)*	$13.1	$15.1	-14% *(-10%)*
TAZVERIK® (tazemetostat)	$0.5	$0.4	+40% *(+46%)*	$0.5	$0.4	+40% *(+46%)*
Oncology Products	**$243.3**	**$101.3**	**+140% *(+145%)***	**$127.8**	**$80.1**	**+59% *(+64%)***
Takeda Upfront, Milestone and R&D services				$33.8	$269.1	-87% *(-87%)*
Other R&D Services[3]				$7.1	$10.0	-29% *(-27%)*
Total Oncology/Immunology				**$168.7**	**$359.2**	**-53% *(-52%)***

[1] For FRUZAQLA®, ELUNATE®, and ORPATHYS®, mainly represents total sales to third parties as provided by Takeda, Lilly and AstraZeneca, respectively.
[2] For FRUZAQLA®, represented drug product supply and royalties paid by Takeda; for ELUNATE®, represented drug product supply, commercial service fees and royalties paid by Lilly, and sales to other third parties invoiced by HUTCHMED; for ORPATHYS®, represented drug product supply and royalties paid by AstraZeneca and sales to other third parties invoiced by HUTCHMED; for SULANDA® and TAZVERIK®, represented HUTCHMED's sales of the products to third parties.
[3] Other R&D services mainly represent cost reimbursement and FTE income from AZ and Lilly.

Strong Cash Position

On path to sustainable business

Condensed Consolidated Balance Sheets

(in US$ millions)

	Jun 30, 2024	Dec 31, 2023
Assets		
Cash, cash equivalents & short-term investments[1]	802.5	886.3
Accounts receivable	156.9	116.9
Other current assets	88.9	93.6
Property, plant and equipment	94.8	99.7
Investment in an equity investee	80.5	48.4
Other non-current assets	37.3	34.9
Total assets	**1,260.9**	**1,279.8**
Liabilities and shareholders' equity		
Accounts payable	43.4	36.3
Other payables, accruals and advance receipts	249.2	271.4
Deferred revenue	108.8	127.1
Bank borrowings[2]	82.1	79.3
Other liabilities	25.4	22.3
Total liabilities	**508.9**	**536.4**
Company's shareholders' equity	**740.1**	**730.6**
Non-controlling interests	11.9	12.8
Total liabilities and shareholders' equity	**1,260.9**	**1,279.8**

As of June 30, 2024

Cash Resources

- **$803m** cash / cash eq. / ST inv.
- **$63m** unutilized banking facilities

Borrowings

- **$82m** in bank borrowings (Dec 31, 2023: $79m)

Others

- **$58m** additional cash at SHPL JV (Dec 31, 2023: $19m)

[1] Short-term investments: deposits over 3 months; [2] Bank borrowings of US$26.5m under current liabilities (Dec 31, 2023: US$31.1m) and US$55.6m under non-current liabilities (Dec 31, 2023: US$48.2m).

Our strategy

Revenue growth & strategic actions on path to self-sustaining

The path to a self-sustaining business

HUTCHMED medium-term & longer-term plan*

AMBITION
to mature into a profitable biopharma

HUTCHMED

VISION
discovering, developing & bringing new innovative medicines to patients worldwide

Sustaining Growth

6-7 products in China and 2-3 globally;
New wave of novel candidates into registration trials



Accelerating Growth

Launch of new products, new indications and in new territories

*Subject to successful clinical development and regulatory approval

Substantial sustainability delivery in 2023

Reduced emissions intensity; delivered on social commitments; developed strategic pillars; tracked Scope 3; enhanced disclosure

Part of our commitment to embedding sustainability into all our operations

ENVIRONMENTAL & SOCIAL

1. Now tracking and disclosing Scope 3 data

(indirect emissions) 2 years ahead of HKEX requirement

2. Reduced intensity of emissions and energy

- **68%** carbon emission intensity in 2023 (vs 2020)
- **58%** energy intensity in 2023 (vs 2020)
- **2.4%** business air travel emission intensity in 2023 (vs 2019)

3. Delivering on commitments to social contributions

Balanced gender diversity

53% female overall

Management 54% female

Full Access to Medicines

All novel medicines now included in National Reimbursement Drug List or named patient programs (Hainan Pilot Zone)

DISCLOSURE & GOVERNANCE

4. 5 sustainability pillars developed

5. Enhanced ESG disclosure

referencing latest standards and guidelines / future requirements

- SASB, ISSB, GRI, TCFD standards
- HKEX, NASDAQ, LSE ESG guidelines/requirements

6. Good progress on 11 sustainability goals & targets

Thank you

HUTCHMED

www.hutch-med.com

References & Abbreviations

ADS = American depositary share.
AIHA = autoimmune hemolytic anemia.
ALK = anaplastic lymphoma kinase.
ALL = acute Lymphoblastic Leukemia
AML = acute myeloid leukemia.
API = active pharmaceutical ingredient.
ASCO = American Society of Clinical Oncology.
ASCO GI = ASCO (American Society of Clinical Oncology) Gastrointestinal Cancers Symposium.
ASH = American Society of Hematology.
bsAb = bi-specific antibody.
BID = twice daily.
BRAF = B-Raf.
BSC = best supportive care.
BTK = bruton's tyrosine kinase.
CBCL= cutaneous B-cell lymphoma.
CER = constant exchange rate.
CI = confidence interval.
CLL/SLL = chronic lymphocytic leukemia and small lymphocytic lymphoma
CRC = colorectal cancer.
CRL = complete response letter.
CSF-1R = colony-stimulating factor 1 receptor.
DCO = data cutoff.
DDI = drug-drug interactions.
DLBCL = diffuse large B-cell lymphoma.
dMMR = deficient mismatch.
DoR = duration of response.
DRR = durable response rate.
epNET = extra-pancreatic neuroendocrine tumor.
EGFR = epidermal growth factor receptor.
EGFRm+ = epidermal growth factor receptor mutated.
EMA = European Medicines Agency.
EMC = endometrial cancer.
Epizyme = Epizyme Inc.
ERK = extracellular signal-regulated kinase.
ES = epithelioid sarcoma.
EU = European Union.
EZH2 = enhancer of zeste homolog 2.
FISH = fluorescence in situ hybridization.
FISH5+ = MET amplification as detected by FISH with MET copy number ≥ 5 and/or MET: CEP signal ratio ≥ 2.
FISH10+ = MET amplification as detected by FISH with MET copy number ≥ 10.
FDA = Food and Drug Administration.
FGFR = fibroblast growth factor receptor.
FL = follicular lymphoma.
FPI = first patient in.
GAAP = Generally Accepted Accounting Principles.
GC = gastric cancer.
GEJ = gastroesophageal junction
GI = gastrointestinal.
HKEX = The Main Board of The Stock Exchange of Hong Kong Limited.
HL = Hodgkin's lymphoma.
HR = hazard ratio.
Hutchison Sinopharm = Hutchison Whampoa Sinopharm Pharmaceuticals (Shanghai) Company Limited.
IDH = Isocitrate dehydrogenase.
In-market sales = total sales to third parties provided by Eli Lilly (ELUNATE®), Takeda (FRUZAQLA®), AstraZeneca (ORPATHYS®) and HUTCHMED (ELUNATE®, SULANDA®, ORPATHYS® and TAZVERIK®).
HCPs = healthcare professionals.
ICI = immune checkpoint inhibitor.
IHC = immunohistochemistry.
IHC50+ = MET overexpression as detected by IHC with 3+ in ≥ 50% tumor cells.
IHC90+ = MET overexpression as detected by IHC with 3+ in ≥ 90% tumor cells.
ILD = interstitial lung disease
iNHL = indolent Non-Hodgkin's Lymphoma.
I/O = Immuno-oncology.
IND = Investigational New Drug (application).
IR = independent review.
IRC = independent review committee.
ITP = Immune thrombocytopenia purpura.
Lilly = Eli Lilly and Company.
MAA = Marketing Authorization Application.
MAPK pathway = RAS-RAF-MEK-ERK signaling cascade.
Mab = monoclonal antibody.
MCL = mantle cell lymphoma.
MDS/MPN = myelodysplastic/myeloproliferative neoplasms.
MET = mesenchymal epithelial transition factor.
MRCT = multi-regional clinical trial.
MSI-H = high levels of microsatellite instability.
MSL: Medical Science Liaison.
MSS / pMMR = microsatellite stable / mismatch repair proficient.
MZL = marginal zone lymphoma.
na = not available.
NDA = New Drug Application.
NEC = neuroendocrine carcinoma.
NETs = neuroendocrine tumors.
NHL = Non-Hodgkin's Lymphoma.
NME = new molecular entity.
NR = not reached.
NRDL = National Reimbursement Drug List.
NSCLC = non-small cell lung cancer.
ORR = objective response rate.
OS = overall survival.
QD = once daily.
PD = progressive disease.
PD-L1 = programmed cell death ligand 1.
PFS = progression-free survival.
PI3Kδ = phosphoinositide 3-kinase delta.
PJP = pneumocystis jirovecii pneumonia.
PMDA = Pharmaceuticals and Medical Devices Agency.
pNET= pancreatic neuroendocrine tumor.
ccRCC = clear cell renal cell carcinoma.
PDAC = pancreatic ductal adenocarcinoma.
pMMR = Proficient mismatch repair.
PRCC = papillary renal cell carcinoma.
PTCL = peripheral T-cell lymphomas.
R&D = research and development.
ROS-1 = c-ros oncogene 1.
SHPL = Shanghai Hutchison Pharmaceuticals Limited.
sNDA = supplemental New Drug Application.
SOC = standard of care.
Syk = spleen tyrosine kinase.
TEAE = treatment emergent adverse events.
TNBC = triple negative breast cancer.
TGCT = tenosynovial giant cell tumor.
TKI = tyrosine kinase inhibitor.
TPO-RA = thrombopoietin receptor agonists.
Tx = treatment.
VEGF = vascular endothelial growth factor.
VEGFR = vascular endothelial growth factor receptor.
VET = venous thromboembolism
wAIHA = warm antibody autoimmune hemolytic anemia.
WM/LPL = Waldenström macroglobulinemia and lymphoplasmacytic lymphoma.
WT = wild-type.
WCLC = IASLC World Conference on Lung Cancer.

APPENDIX

Fruquintinib with sintilimab 2L RCC: PD-1 antibody combinations

HUTCHMED

No PD-1/VEGFi combo approved in 1L or 2L RCC in China

Robust and durable responses seen in previously treated advanced RCC

ASCO 2023	Fruquintinib + Sintilimab P2 POC Study [1]	CONTACT-03 [2] Cabozantinib +/- atezolizumab		KEYMAKER-U03 [3] Belzutifan + lenvatinib	Lenvatinib + pembrolizumab (KEYNOTE-146) [4]	
		Cabozantinib	Atezolizumab + cabozantinib	Arm 5	ICI naïve	ICI pretreated
TKI dose	*5mg QD 2 weeks on / 1 week off*	*60mg QD*		*20 mg QD*	*20 mg QD*	
Data cut-off date	Nov 30, 2022	January 3, 2023		Sept 29, 2022	August 18, 2020	
Median f/u duration	23.3 months	15.2 months		6.9 months	19.8 months	
N	20	259	263	24	17	104
ORR *[95% CI]*	60.0%	40.9% *[34.8 to 47.3]*	40.5% *[34.5 to 46.8]*	50% *[29 to 71]*	52.9% *[27.8 to 77.0]*	62.5% *[52.5 to 71.8]*
DCR *[95% CI]*	85.0%	88.5%	91.1%	88%	94.1% *[71.3 to 99.9]*	92.3% *[85.4 to 96.6]*
mDoR, months *[95% CI]*	n/a	14.8 *[11.3 to 20.0]*	12.7 *[9.8 to 12.3]*	NR	9.0 *[3.5 to NR]*	12.5 *[9.1 to 17.5]*
mPFS, months *[95% CI]*	***15.9***	***10.8*** *[10.0 to 12.5]*	***10.6*** *[9.8 to 12.3]*	**11.2** *[4.2 to NR]*	**11.8** *[5.5 to 21.9]*	**12.2** *[9.5 to 17.7]*

[1] ASCO 2023 *J Clin Oncol* 41, 2023 (suppl 16; abstr e16514), DOI: 10.1200/JCO.2023.41.16_suppl.e16514; [2] ASCO 2023 *J Clin Oncol* 41, 2023 (suppl 17; abstr LBA4500), DOI: 10.1200/JCO.2023.41.17_suppl.LBA4500; [3] ASCO 2023 *J Clin Oncol* 41, 2023 (suppl 16; abstr 4553), DOI: 10.1200/JCO.2023.41.16_suppl.4553; [4] Lee CH, et al. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. *Lancet Oncol.* 2021;22(7):946-958. doi:10.1016/S1470-2045(21)00241-2.

Sovleplenib: warm antibody autoimmune hemolytic anemia (wAIHA)

No disease-targeted therapies approved, despite the unmet medical need that exists for these patients

AIHA Incidence:
0.8-3.0/100,000[1]

AIHA Prevalence:
9.5-17/100,000[2] [3]

wAIHA represents
75-80% of AIHA case[4]

Death rate: 8% - 11%[5]

[1] Eaton WW, Rose NR, Kalaydjian A, Pedersen MG, Mortensen PB. Epidemiology of autoimmune diseases in Denmark. J Autoimmun. 2007; 29 (1):1-9. doi: 10.1016/j.jaut.2007.05.002.
[2] Roumier M, Loustau V, Guillaud C, et al. Characteristics and outcome of warm autoimmune hemolytic anemia in adults: new insights based on a single-center experience with 60 patients. Am J Hematol. 2014; 89 (9):E150-5. doi: 10.1002/ajh.23767.
[3] Hansen D.L., Möller S., Andersen K., Gaist D., Frederiksen H. Increasing Incidence and Prevalence of Acquired Hemolytic Anemias in Denmark, 1980–2016. Clin. Epidemiol. 2020;12:497–508. doi: 10.2147/CLEP.S250250
[4] Gehrs BC, Friedberg RC. Autoimmune haemolytic anemia. Am J Hematol. 2002; 69:258–271. doi: 10.1002/ajh.10062.
[5] Cotran Ramzi S, Kumar Vinay, Fausto Nelson, Nelso Fausto, Robbins Stanley L, Abbas Abul K. Robbins and Cotran pathologic basis of disease. St. Louis, Mo: Elsevier Saunders; 2005. p. 637.

Sovleplenib:
our first potential novel medicine in autoimmune diseases

HUTCHMED

ITP (ESLIM-01)

An efficacious and tolerable treatment option for ITP patients, even in heavily treated patients (75% failed TPO/TPO-RA)

- Durable response: **48%**; overall response: **71%**
- Fast onset with a median of 8 days
- Significant improvement of QoL
- Well-tolerated with low GI toxicities, hypertension and no thrombotic events
- International ITP Phase Ib trial (US, EU, AU) open for enrollment

wAIHA (ESLIM-02)

Encouraging results for wAIHA patients

- Durable response: **47.6%**; overall response: **66.7%**
- Patients crossed over from placebo also achieved a similar high response as in all patients
- A rapid and sustained improvement in hemoglobin levels
- A stable response maintained over a 24-week treatment period

Potential Future Development

- 2L+ ITP post-TPO-RA or TPO-RA naïve
- 1L ITP patients who are not candidates for glucocorticoids treatment (elderly, diabetic, etc.)
- Combination with SOC in earlier line ITP
- Secondary ITP
- Other autoimmune diseases